Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) reported inducement stock option grants effective April 17, 2026, totaling 855,000 shares to nine newly hired employees.

The options carry a $1.68 exercise price (closing price on the grant date), a 10-year term, and vest over four years with a 12.5% six-month cliff.

AI-generated analysis. Not financial advice.

News Market Reaction – GERN

-3.85%

11 alerts

-3.85% News Effect

-8.7% Trough in 26 hr 2 min

-$41M Valuation Impact

$1.03B Market Cap

0.8x Rel. Volume

On the day this news was published, GERN declined 3.85%, reflecting a moderate negative market reaction. Argus tracked a trough of -8.7% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $41M from the company's valuation, bringing the market cap to $1.03B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement option shares: 855,000 shares New hires: 9 employees Exercise price: $1.68 per share +4 more

7 metrics

Inducement option shares 855,000 shares Aggregate stock options to nine new employees

New hires 9 employees Employees receiving inducement stock options

Exercise price $1.68 per share Equal to GERN closing price on April 17, 2026 grant date

Option term 10 years Life of inducement stock options

Vesting period 4 years Overall vesting duration for option awards

Initial vesting tranche 12.5% Vests at six-month employment anniversary

Remaining vesting 42 months Equal installments after initial six-month cliff

Market Reality Check

Price: $1.2800 Vol: Volume 23,658,774 is 11% ...

normal vol

$1.2800 Last Close

Volume Volume 23,658,774 is 11% above the 20-day average of 21,329,069. normal

Technical Price at $1.68, trading above the 200-day MA at $1.39 and 16.4% below the 52-week high of $2.01.

Peers on Argus

GERN slipped 0.59% while key biotech peers showed mixed moves, with names like A...

1 Up

GERN slipped 0.59% while key biotech peers showed mixed moves, with names like AVXL, IMNM, QURE, and TSHA up between 3.11% and 5.41% and ZBIO down 0.77%. Momentum scans flagged only 1 peer (PRAX, up 0.59%), suggesting a stock-specific backdrop rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Apr 14 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 14	Inducement stock option	Neutral	-4.5%	Large inducement option grant to new executive under Nasdaq Rule 5635(c)(4).
Apr 13	Executive appointment	Positive	+3.6%	Appointment of new Executive Vice President and Chief Legal Officer.
Apr 06	Conference participation	Positive	+5.4%	Announcement of participation in Needham healthcare conference webcast.
Mar 26	Board appointments	Positive	-1.9%	Addition of two experienced biopharma leaders to Board of Directors.
Mar 18	Inducement stock options	Neutral	+0.0%	Inducement options totaling 956,250 shares to six new hires.

Pattern Detected

Recent inducement grants and governance updates have typically led to modest and sometimes mixed price reactions, with more substantive events like conferences and executive appointments skewing positive.

Recent Company History

Over the last month, Geron has repeatedly used inducement stock options and governance moves alongside commercial execution. On March 18, 2026 and April 14, 2026, Geron reported inducement grants under Nasdaq Rule 5635(c)(4), with flat to negative next-day moves. Management strengthened its leadership bench on March 26, 2026 with new board members and on April 13, 2026 with a new Chief Legal Officer, while also presenting at the Needham healthcare conference on April 13, 2026. Today’s additional inducement awards fit this pattern of ongoing hiring and corporate build-out.

Market Pulse Summary

This announcement details standard inducement stock option grants for nine new hires, totaling 855,0...

Analysis

This announcement details standard inducement stock option grants for nine new hires, totaling 855,000 shares at an exercise price of $1.68 and vesting over 4 years. It follows similar grants reported on March 18, 2026 and executive-focused awards on April 14, 2026, underscoring ongoing team build-out after prior restructuring. Investors may watch the scale and frequency of such awards alongside regulatory filings and future earnings to gauge dilution trends and execution on the RYTELO commercialization strategy.

Key Terms

nasdaq listing rule 5635(c)(4), stock options, exercise price, vesting, +2 more

6 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted by the Compensation Committee ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"it granted stock options to purchase an aggregate of 855,000 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The stock options have an exercise price of $1.68 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"and vest over four years, with 12.5% of the shares underlying the options vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

inducement award plan financial

"subject to the terms and conditions of Geron’s 2018 Inducement Award Plan"

An inducement award plan is a package of pay, often including stock options or restricted shares, granted to a new employee or executive to attract them to join a company — think of it like a signing bonus paid partly in company stock. Investors care because these awards increase compensation expense and can dilute existing shareholders’ ownership, affecting earnings per share and incentives that shape company strategy.

stock option agreement financial

"and the form of stock option agreement under the plan"

A stock option agreement is a formal contract that gives an individual the right to buy or sell a specific number of shares of a company's stock at a set price within a certain period. For investors, it’s an important tool because it can provide opportunities to profit from stock price movements or to protect against potential losses, making it a key element in financial planning and investment strategies.

AI-generated analysis. Not financial advice.

FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.68 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.

The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO^® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com

FAQ

What inducement grants did Geron (GERN) announce on April 20, 2026?

Geron granted stock options to purchase 855,000 shares to nine new employees. According to Geron, the options were effective April 17, 2026, and were approved under Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and term of the Geron (GERN) inducement options?

The options have an exercise price of $1.68 per share and a 10-year term. According to Geron, $1.68 equals the closing price on the grant date.

How do the Geron (GERN) inducement stock options vest?

Options vest over four years with 12.5% vesting at the six-month anniversary, then equal monthly installments over 42 months. According to Geron, vesting is subject to continued employment.

Under what plan and rule were Geron's (GERN) inducement awards granted?

The awards were granted under Geron's 2018 Inducement Award Plan and the form stock option agreement. According to Geron, the Compensation Committee approved them under Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement awards from Geron (GERN)?

Nine newly hired employees received inducement stock options totaling 855,000 shares. According to Geron, these grants were material to the employees' acceptance of employment.

Will Geron's (GERN) inducement grants dilute existing shareholders?

The press release details 855,000 option shares but does not quantify dilution impact. According to Geron, the grants follow Nasdaq rule 5635(c)(4) and the 2018 Inducement Award Plan.